A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: [14C]Ulonivirine

Study type: Interventional

Funder types: Industry

Identifiers

NCT07334886

MK-8507-006 (Other Identifier)

8507-006

Details and patient eligibility

About

The goal of this study is to learn how [14C]ulonivirine moves through a healthy person's body over time. Researchers will study how [14C]ulonivirine is absorbed by the body, broken down by the body, and how it leaves the body.

Enrollment: 8 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria include but are not limited to:

• Is in good health
• Has a body mass index (BMI) of 18 to 32 kg/m^2

Key Exclusion Criteria include but are not limited to:

• Has a history of cancer
• Has positive tests for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus antibody

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

[14C]Ulonivirine

Experimental group

Description:

All participants receive a single oral dose of \[14C\]ulonivirine on Day 1.

Treatment:

Drug: [14C]Ulonivirine